Vascular Biogenics Ltd. (VBLT) Income Statement Analysis

See more : Rishabh Instruments Limited (RISHABH.NS) Income Statement Analysis – Financial Results

Complete financial analysis of Vascular Biogenics Ltd. (VBLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vascular Biogenics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Dynapac Co., Ltd. (3947.T) Income Statement Analysis – Financial Results
Maja Agung Latexindo Tbk. (SURI.JK) Income Statement Analysis – Financial Results
Indian Railway Catering & Tourism Corporation Limited (IRCTC.NS) Income Statement Analysis – Financial Results
FTAC Zeus Acquisition Corp. (ZINGW) Income Statement Analysis – Financial Results
Sinclair Broadcast Group, Inc. (SBGI) Income Statement Analysis – Financial Results

Vascular Biogenics Ltd. (VBLT)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.vblrx.com

About Vascular Biogenics Ltd.

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	658.00K	768.00K	922.00K	562.00K	585.00K	13.86M	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	104.00K	365.00K	394.00K	163.00K	235.00K	340.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	554.00K	403.00K	528.00K	399.00K	350.00K	13.52M	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	84.19%	52.47%	57.27%	71.00%	59.83%	97.55%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	21.65M	22.70M	19.66M	15.47M	15.94M	17.77M	12.45M	11.20M	10.97M	13.51M	10.57M
General & Administrative	11.75M	7.70M	5.36M	4.83M	5.15M	5.80M	3.79M	3.64M	3.77M	2.41M	1.89M
Selling & Marketing	0.00	0.00	0.00	0.00	397.00K	562.00K	0.00	0.00	0.00	0.00	0.00
SG&A	11.75M	7.70M	5.36M	4.83M	5.55M	6.36M	3.79M	3.64M	3.77M	2.41M	1.89M
Other Expenses	0.00	0.00	0.00	115.00K	70.00K	0.00	42.00K	34.00K	33.00K	43.00K	12.00K
Operating Expenses	33.41M	30.40M	25.01M	20.41M	21.56M	24.18M	16.28M	14.87M	14.78M	15.96M	12.47M
Cost & Expenses	33.51M	30.76M	25.41M	20.58M	21.79M	24.52M	16.28M	14.87M	14.78M	15.96M	12.47M
Interest Income	634.00K	120.00K	363.00K	870.00K	908.00K	335.00K	263.00K	100.00K	15.00K	27.00K	236.00K
Interest Expense	85.00K	44.00K	105.00K	313.00K	0.00	0.00	0.00	117.00K	0.00	0.00	0.00
Depreciation & Amortization	1.69M	120.00K	1.56M	2.58M	1.16M	156.00K	130.00K	122.00K	135.00K	169.00K	197.00K
EBITDA	-31.16M	-29.88M	-22.93M	-17.43M	-19.93M	-10.71M	-16.17M	-14.65M	-14.35M	-16.00M	-12.29M
EBITDA Ratio	-4,735.71%	-3,890.10%	-2,486.55%	-3,101.42%	-3,406.67%	-77.24%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-32.85M	-30.00M	-24.48M	-20.01M	-21.21M	-10.66M	-16.28M	-14.87M	-14.78M	-15.96M	-12.47M
Operating Income Ratio	-4,992.86%	-3,905.73%	-2,655.42%	-3,561.21%	-3,625.13%	-76.85%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	549.00K	76.00K	258.00K	557.00K	749.00K	517.00K	273.00K	-17.00K	-2.63M	-1.41M	244.00K
Income Before Tax	-32.30M	-29.92M	-24.23M	-19.46M	-20.46M	-10.14M	-16.00M	-14.89M	-17.41M	-17.37M	-12.23M
Income Before Tax Ratio	-4,909.42%	-3,895.83%	-2,627.44%	-3,462.10%	-3,497.09%	-73.12%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-85.00K	-1.21M	105.00K	313.00K	-749.00K	-517.00K	-273.00K	17.00K	2.63M	1.41M	-244.00K
Net Income	-32.22M	-28.71M	-24.33M	-19.77M	-20.46M	-10.14M	-16.00M	-14.89M	-17.41M	-17.37M	-12.23M
Net Income Ratio	-4,896.50%	-3,738.02%	-2,638.83%	-3,517.79%	-3,497.09%	-73.12%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.42	-0.41	-0.56	-0.55	-0.62	-0.37	-0.64	-0.73	-3.09	-1.44	-1.01
EPS Diluted	-0.42	-0.41	-0.56	-0.55	-0.62	-0.37	-0.64	-0.73	-3.09	-1.44	-1.01
Weighted Avg Shares Out	77.55M	69.33M	43.67M	35.88M	32.97M	27.40M	24.97M	20.31M	5.63M	12.05M	12.05M
Weighted Avg Shares Out (Dil)	77.55M	69.33M	43.67M	35.88M	32.97M	27.40M	24.97M	20.31M	5.63M	12.05M	12.05M

Amalgamated Bank Reduces Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 20, 2024https://www.defenseworld.net

Amalgamated Bank lessened its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,561 shares of...

Notable Labs Closes Merger Transaction With VBL Therapeutics

October 16, 2023globenewswire.com

- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 -

VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

October 12, 2023globenewswire.com

Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI'IN, Israel and NEW YORK,...

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

October 4, 2023globenewswire.com

Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October...

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

September 6, 2023globenewswire.com

Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI'IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its...

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 28, 2023businesswire.com

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the “Company”) (NasdaqGM: VBLT)...